The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations.
Pear Therapeutics received market authorization from the FDA for its insomnia digital therapeutic, Somryst. It is Pear’s third product to receive FDA clearance, and the first product to be reviewed under the FDA's new software precertification pilot program.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Treatment for depression, anxiety and insomnia doesn't necessarily need to be provided with the help of pharmaceuticals. Caputron is demonstrating that with its mindGear device.
Dependence on sleeping pills is a problem for many people, but other therapies aren't always very successful. The designer of SleepCogni believes his device is the answer to not just monitoring sleep, but actually inducing it.
Another digital health sleep product will land in the U.S. later this year via a London-based company that’s just gotten its first venture round to expand. Big Health delivers personalized cognitive behavioral therapy programs through web and mobile platforms. Its first offering, Sleepio, is a six-week sleep improvement program that teaches people techniques to overcome […]